Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test

Behavioural Brain Research

Volumn 225, Issue 1, 2011, Pages 328-333

  Moretti, Morgana ^a   Freitas, Andiara Espindola de ^a   Budni, Josiane ^a   Fernandes, Sinara Castellen Pereira ^a   Balen, Grasiela de Oliveira ^a   Rodrigues, Ana Lúcia Severo ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Ascorbic acid; Depression; L arginine; Nitric oxide; NMDA; Tail suspension test

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 7 NITROINDAZOLE; ARGININE; ASCORBIC ACID; CYCLIC GMP; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; SILDENAFIL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTAL TEST; FEMALE; IMMOBILIZATION; LOCOMOTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; TAIL SUSPENSION TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE; ASCORBIC ACID; CYCLIC GMP; DEPRESSION; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; FEMALE; HINDLIMB SUSPENSION; INDAZOLES; MICE; N-METHYLASPARTATE; NITRIC OXIDE; OXADIAZOLES; PIPERAZINES; PURINES; QUINOXALINES; SIGNAL TRANSDUCTION; SULFONES;

EID: 80051878511     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.07.024     Document Type: Article

References (48)

1. Belmaker R.H., Agam G. Major depressive disorder. N Eng J Med 2008, 358:55-68.
2. Kessler R.C., Akiskal H.S., Ames M., Birnbaum H., Greenberg P., Hirschfeld R.M., et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry 2006, 163:1561-1568.
3. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539.
4. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61:105-123.
5. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry; 2010: in press, doi:10.1016/j.pnpbp.2010.06.013.
6. Paul I.A., Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003, 1003:250-272.
7. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
8. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Stertz L., Kapczinski F., et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:450-455.
9. Esplugues J.V. NO as a signalling molecule in the nervous system. Brit J Pharmacol 2002, 135:79-1095.
10. Denninger J.W., Marletta M.A. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1999, 1411:334-350.
11. Harkin A.J., Bruce K.H., Craft B., Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999, 372:207-213.
12. da Silva G., Matteussi A., Santos A.R.S., Calixto J.B., Rodrigues A.L.S. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuro Report 2000, 11:3699-3702.
13. Mantovani M., Pértile R., Calixto J.B., Santos A.R.S., Rodrigues A.L.S. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neurosci Lett 2003, 343:1-4.
14. Brocardo P.S., Budni J., Lobato K.R., Kaster M.P., Rodrigues A.L.S. Antidepressant-like effect of folic acid: involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur J Pharmacol 2008, 598:37-42.
15. Chatterjee I.B., Majumder A.K., Nandi B.K., Subramanian N. Synthesis and some major functions of vitamin C in animals. Ann N Y Acad Sci 1975, 258:24-47.
16. Majewska M.D., Bell J.A., London E.D. Regulation of the NMDA receptor by redox phenomena: inhibitory role of ascorbate. Brain Res 1990, 537:328-332.
17. Majewska M.D., Bell J.A. Ascorbic acid protects neurons from injury induced by glutamate and NMDA. Neuroreport 1990, 1:194-196.
18. Rebec G.V., Pierce R.C. A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. Prog Neurobiol 1994, 43:537-565.
19. Rosa K.A., Gadotti V.M., Rosa A.O., Rodrigues A.L.S., Calixto J.B., Santos A.R.S. Evidence for the involvement of glutamatergic system in the antinociceptive effect of ascorbic acid. Neurosci Lett 2005, 381:185-188.
20. Zuo D.Y., Zhang Y.H., Cao Y., Wu C.F., Tanaka M., Wu Y.L. Effect of acute and chronic MK-801 administration on extracellular glutamate and ascorbic acid release in the prefrontal cortex of freely moving mice on line with open-field behavior. Life Sci 2006, 78:2172-2178.
21. Harrison F.E., May J.M. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med 2009, 46:719-730.
22. Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial. Biol Psychiatry 2002, 52:371-374.
23. Cocchi P., Silenzi M., Calabri G., Salvi G. Antidepressant effect of vitamin C. Pediatrics 1980, 65:862-863.
24. Binfaré R.W., Rosa A.O., Lobato K.R., Santos A.R.S., Rodrigues A.L.S. Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:530-540.
25. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
26. Almeida R.C., Felisbino C.S., López M.G., Rodrigues A.L.S., Gabilan N.H. Evidence for the involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav Brain Res 2006, 168:318-322.
27. Ghasemi M., Sadeghipour H., Mosleh A., Sadeghipour H.R., Mani A.R., Dehpour A.R. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur Neuropsychopharmacol 2008, 18:323-332.
28. Kaster M.P., Rosa A.O., Santos A.R.S., Rodrigues A.L.S. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int J Neuropsychopharmacol 2005, 8:601-606.
29. Kulkarni S.K., Dhir A. Possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant-like activity of berberine chloride. Eur J Pharmacol 2007, 569:77-83.
30. Rosa A.O., Lin J., Calixto J.B., Santos A.R.S., Rodrigues A.L.S. Involvement of NMDA receptors and l-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res 2003, 144:87-93.
31. Zomkowski A.D., Engel D., Gabilan N.H., Rodrigues A.L.S. Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. Eur Neuropsychopharmacol 2010, 20:793-801.
32. Bourin M., Chenu F., Ripoll N., David D.J.P. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 2005, 164:266-269.
33. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
34. Bourin M., Fiocco A.J., Clenet F. How valuable are animal models in defining antidepressant activity?. Hum Psychopharmacol 2001, 16:9-21.
35. Wong M.L., Licinio J. Research treatment approaches to depression. Nat Rev Neurosci 2001, 2:343-351.
36. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999, 7:125-143.
37. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004, 9:984-997.
38. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
39. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375:31-40.
40. Gozlan H., Ben-Ari Y. NMDA receptor redox sites: are they targets for selective neuronal protection?. Trends Pharmacol Sci 1995, 16:368-374.
41. Yildiz F., Erden B.F., Ulak G., Utkan T., Gacar N. Antidepressant-like effects of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 2000, 149:41-44.
42. Karolewicz B., Paul I.A., Michaluk L.A. Effect of NOS inhibitor on forced swim test and neurotransmitters turnover in the mouse brain. Pol J Pharmacol 2001, 53:587-596.
43. Harkin A.J., Connor T.J., Walsh M., St John N., Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003, 44:616-623.
44. Volke V., Wegener G., Bourin M., Vasar E. Antidepressant and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res 2003, 140:141-147.
45. Krass M., Wegener G., Vasar E., Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011, 218:57-63.
46. Zhou Q.G., Hu Y., Hua Y., Hu M., Luo C.X., Han X., et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 2007, 103:1843-1854.
47. Dhir A., Kulkarni S.K. Involvement of l-arginine-nitric oxide cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:921-925.
48. Beavo J.A. cGMP inhibition of heart phosphodiesterase: is it clinically relevant?. J Clin Invest 1995, 95:445.